ProtAb ^Companies

ProtAb is an organization that focuses on developing therapeutic agents to modulate cytokine regulation, specifically targeting anti-inflammatory signaling pathways. Their main goal is to provide effective treatment options for autoimmune and inflammatory diseases. Their flagship product, Prozumab, is a monoclonal antibody with a unique mechanism of action. Currently, Prozumab is in late-stage preclinical development for the treatment of inflammatory bowel disease, ulcerative colitis, and rheumatoid arthritis. ProtAb operates as a subsidiary of Hadasit Bio-Holdings, which is a publicly traded subsidiary of Hadasit, the technology transfer company of Hadassah University Hospital in Jerusalem, Israel.